PMID- 27848915
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20170210
IS  - 1950-6112 (Electronic)
IS  - 0003-3898 (Linking)
VI  - 74
IP  - 6
DP  - 2016 Dec 1
TI  - Heparin monitoring: clinical outcome and practical approach.
PG  - 637-652
AB  - Traditional anticoagulant agents such as unfractionated heparin (UFH), low 
      molecular weight heparins (LMWHs), fondaparinux, danaparoid and bivalirudine are 
      used in the prevention and treatment of thromboembolic diseases. However, these 
      agents have limitations: their constraining parenteral route of administration 
      and the need for regular coagulation monitoring for HNF. The LMWHs, with their 
      more predictable anticoagulant response, don't require a systematic monitoring. 
      The usefulness of LMWHs monitoring in several clinical situations such as 
      pregnancy, obesity and renal insufficiency is a matter of debate. Indeed, there 
      is no agreement between French and American recommendations on this question. 
      Others aspects are also controversial: the measure of trough anti-Xa activity 
      during pregnancy and the optimal monitoring of LMWHs for patients with 
      antithrombin deficiency (hepatic disease, new-borns). Different tests are 
      available to ensure the monitoring of these drugs, we will see in this review 
      their principle, their advantages and inconvenients. The management of heparin 
      induced thrombocytopenia also needs parenteral anticoagulants: danaparoid, 
      bivalirudine or argatroban. The modalities of their monitoring are relatively 
      unknown and are presented. Furthermore, platelet monitoring is capital. This 
      article aims to provide guidance about laboratory testing of classic parenteral 
      anticoagulants.
FAU - Despas, Noemie
AU  - Despas N
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Hematology-hemostasis laboratory, Yvoir, Belgique.
FAU - Larock, Anne-Sophie
AU  - Larock AS
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Department of pharmacy, Yvoir, Belgique.
FAU - Jacqmin, Hugues
AU  - Jacqmin H
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Hematology-hemostasis laboratory, Yvoir, Belgique.
FAU - Douxfils, Jonathan
AU  - Douxfils J
AD  - Department of pharmacy, Namur thrombosis and hemostasis center (NTHC), Namur 
      research institute for life sciences (NARILIS), Universite de Namur, Namur, 
      Belgique.
FAU - Chatelain, Bernard
AU  - Chatelain B
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Hematology-hemostasis laboratory, Yvoir, Belgique.
FAU - Chatelain, Marc
AU  - Chatelain M
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Hematology-hemostasis laboratory, Yvoir, Belgique.
FAU - Mullier, Francois
AU  - Mullier F
AD  - Universite catholique de Louvain, CHU UCL Namur, Namur thrombosis and hemostasis 
      center, Hematology-hemostasis laboratory, Yvoir, Belgique.
LA  - eng
PT  - Journal Article
PT  - Review
TT  - Suivi biologique de l'heparinotherapie : interet clinique et aspects pratiques.
PL  - France
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Drug Monitoring/*methods
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - Thromboembolism/diagnosis/*drug therapy/*prevention & control
MH  - Treatment Outcome
OTO - NOTNLM
OT  - fondaparinux
OT  - low molecular weight heparins
OT  - monitorin
OT  - unfractionated heparin
EDAT- 2016/11/17 06:00
MHDA- 2017/02/12 06:00
CRDT- 2016/11/17 06:00
PHST- 2016/11/17 06:00 [entrez]
PHST- 2016/11/17 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
AID - abc.2016.1198 [pii]
AID - 10.1684/abc.2016.1198 [doi]
PST - ppublish
SO  - Ann Biol Clin (Paris). 2016 Dec 1;74(6):637-652. doi: 10.1684/abc.2016.1198.